Osteal Therapeutics Stock

Osteal Therapeutics, founded in 2013, is a biopharmaceutical company that striving to develop novel musculoskeletal therapeutics with the goal of treating infections that affect orthopedic systems. The company has developed a treatment called VT-X7, which is for periprosthetic joint infection (PJI), a rare complication that can occur during joint replacement surgeries. The treatment aims to target affected tissues directly with antibiotics and is intended to be more effective than traditional PJI treatments. Osteal Therapeutics is headquartered in Dallas, Texas.